Hypertension Treatment Set for Disruptive Breakthrough: U.S. Giants Join Forces for Pivotal 2026 Trial Push

May 14, 2026 08:01 CST Updated 08:01

Orchestra BioMed

Cardiovascular Disease Drug Developer

Medtronic

Medical Device Manufacturer

Families! For patients with hypertension, today's news is absolutely worth collecting and sharing — the treatment of hypertension, which affects hundreds of millions of people worldwide, may be ushering in a whole new possibility of "drug-free blood pressure reduction"!

On May 13, U.S.-listed company Orchestra BioMed (NASDAQ: OBIO) officially announced that its BACKBEAT cardiac pacing clinical trial for hypertension is expected to complete the enrollment of all patients by the end of the third quarter of 2026, bringing this novel therapy one step closer to realization. ✅

Some may ask: With so many antihypertensive drugs on the market, what makes this new therapy so special? Hold on, let me explain it in simple terms—once you finish reading, you'll understand just how valuable it is!

01.Breaking the "Can't Stop the Medicine" Dilemma! This Therapy Achieves Blood Pressure Reduction Through "Cardiac Pacing"

Orchestra BioMed BackBeat cardiac neuromodulation therapy

We all know that most patients with hypertension have to take medication for a long time, some even need to take 2-3 types of drugs. It's not only troublesome but also may face side effects. Moreover, many people who stop taking medication without authorization experience blood pressure rebound, increasing the risk of heart attack and stroke. However, the new therapy developed by Orchestra BioMed completely breaks away from the traditional approach of "taking pills to lower blood pressure."

Its core technology is called AVIM (Atrioventricular Interval Modulation), which, in simple terms, uses a conventional dual-chamber pacemaker to stimulate the heart's conduction system, achieving an "immediate, significant, and lasting" blood pressure reduction effect—no need to take medication daily; stable blood pressure control can be achieved with just one device. This is undoubtedly a groundbreaking breakthrough in the field of hypertension treatment!

More notably, this AVIM therapy received the "Breakthrough Device Designation" from the U.S. FDA (Food and Drug Administration) in April this year. Those familiar with the medical field know that this designation is a “fast track” provided by the FDA for innovative devices that address unmet medical needs and have significant clinical value. Obtaining it means that the safety and efficacy of this therapy have received preliminary official recognition, and the subsequent approval process will be significantly expedited.

02.Key Timeline Confirmed! 2026-2027, Witness New Medical Breakthroughs

The core of Orchestra BioMed's official announcement this time is the clarification of the key time nodes for the BACKBEAT clinical trial. We will use a clear timeline to help everyone focus on the key points:

End of the third quarter of 2026: Completed the recruitment of all patients for the BACKBEAT clinical trial. The trial has now advanced globally, and the FDA has also approved the application to "reduce the sample size" — originally requiring more participants, but now optimized to only recruit 316 patients, of which 284 can be used for efficacy evaluation, saving time while ensuring the scientific rigor and precision of the trial.
Q2 2027Orchestra BioMed, in collaboration with medical giant Medtronic, will submit the primary endpoint data of the clinical trial and announce it at an international medical conference — this means that by then, we will be able to see the specific blood pressure-lowering effects, safety, and other core data of this therapy, bringing it one step closer to clinical application.
Follow-up Planning: If the clinical trial meets the expected goals, Medtronic will immediately submit an application to the FDA for market approval. After obtaining approval in the U.S. market, it will gradually advance regulatory approvals in other regions globally, which is expected to benefit hypertension patients worldwide in the future.

It must be mentioned here that Orchestra BioMed is not fighting alone. Its partner is Medtronic, a global medical giant with decades of expertise in cardiac pacing and exceptional technology and market strength in the cardiovascular device field. The collaboration between these two powerhouses undoubtedly provides double assurance for the implementation of this new therapy.

03.Why Is It Called a "Milestone Breakthrough"? Hear What the Industry Leaders Have to Say

Regarding the potential of this new therapy, the senior executives of Orchestra BioMed and Medtronic have given high praise. Let's translate it into plain language for everyone:

Orchestra BioMed Chairman and CEO David Hochman stated, "We are pleased to clarify the overall timeline for the BACKBEAT trial, which is driven by strong global recruitment momentum and the FDA's recognition of the optimized trial sample size. We believe the BACKBEAT trial will serve as a landmark pivotal study, paving the way for an entirely new treatment approach for patients at high risk of hypertension and hypertensive heart disease."

In simple terms, they are confident in this therapy, believing it can break the current treatment pattern and bring new hope to patients troubled by hypertension — especially those who do not respond well to medication or cannot tolerate drug side effects, as they may finally find their "salvation."

Dr. Robert C. Kowal, Vice President and General Manager of Medtronic's Cardiac Rhythm Management business for pacemaker therapy, also added: "For decades, cardiac pacing has been a core approach in treating arrhythmias, and through the BACKBEAT trial, we hope to extend the benefits of pacing into the field of hypertension treatment to help more high-risk patients. This update to the timeline also reflects our shared confidence in the progress of the trial, data submission, and demonstration of clinical evidence."

04.What Should Ordinary People Focus On? These 2 Points Are Crucial

Patients with hypertension may ask: When will this therapy be available? Can we sign up for the trial now?

First, the BACKBEAT trial is currently still in the patient recruitment phase, primarily targeting patients with hypertension (specific recruitment criteria can be found in official announcements to follow). Second, according to the timeline, core data will not be available until at least 2027, and subsequent FDA approval, global promotion, and actual availability to general patients will likely take additional time.

But everyone can focus on two key points:

The core advantage of this therapy is "drug-free, long-lasting blood pressure reduction." If implemented, it will completely change the current situation where hypertension patients have to "take medication every day," especially suitable for those who do not respond well to drugs or cannot tolerate side effects, filling the gap in traditional treatments.
It was jointly developed by Orchestra BioMed and Medtronic, with FDA Breakthrough Device Designation to ensure its technology and safety. Once it hits the market, it will most likely become the "new benchmark" for hypertension treatment.

05.Finally, I would like to say

Data shows that China has about 245 million adult patients with hypertension, and an increasing number of young people are joining the ranks of those with high blood pressure. "Unstable blood pressure, medication can't stop" has become a困扰 for many people.

The advancement of this AVIM therapy is not only a breakthrough in medical technology but also a blessing for countless patients with hypertension. We will continue to follow the progress of the BACKBEAT trial and synchronize the latest news with everyone in the first instance.

Share this article with family and friends around you who are troubled by hypertension, and together look forward to the early implementation of this "drug-free blood pressure reduction" new therapy, allowing more people to get rid of the troubles of hypertension and enjoy a healthier life ❤️

PS: Follow me for continuous updates on global medical technology breakthroughs, bringing you the latest information on cutting-edge therapies to protect the health of you and your family~